Provided are a nitroxoline prodrug and a use thereof. Specifically, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a composition containing the compound, and a use thereof in the preparation of anti-infective and antitumor drugs, and definitions of groups in formula (I) are as stated in the specification. The compound represented by formula (I) has better pharmacokinetic parameters such as solubility, blood medicine concentration, or half-life period than nitroxoline. The compound represented by formula (I) can reduce the frequency of drug administration, and has potential for application in other fields other than the field of urinary tracts.
2‐Bromoallobetulone (2 b) methyl 2‐bromobetulonate (3 b), 2‐bromooleanonic acid (5 b), and 2‐thiocyanooleanonic acid (5 c) were best, with IC50 values less than 10 μm against CCRF‐CEM cells (e.g., 3 b: IC50=2.9 μm) as well as 2′‐(diethylamino)olean‐12(13)‐eno[2,3‐d]thiazole‐28‐oic acid (5 f, IC50=9.7 μm) and 2′‐(N‐methylpiperazino)olean‐12(13)‐eno[2,3‐d]thiazole‐28‐oic acid (5 k, IC50=11.4 μm). Compound 5 c leads to
Preparation of an ABC tricyclic model of the cylindrospermopsin alkaloids via a biomimetically inspired pathway
作者:Daniel. M. Evans、Peter N. Horton、Michael B. Hursthouse、Patrick. J. Murphy
DOI:10.1039/c4ra03031a
日期:——
The protected guanidine18was convertedviaa 4-step sequence (Boc-deprotection, tethered Biginelli condensation, deallylation/decarboxylation and reduction) to give the tricyclic guanidines26and27, models of the tricyclic core of cylindrospermopsin1.